| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 19, 2022
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022....
-
Nov 15, 2021Closing of the Sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD105M
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for...
-
Oct 15, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that it has closed on the...
-
Sep 28, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that its subsidiary...
-
Aug 16, 2021Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh)
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – August 16, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Aug 9, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –August 9, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, its subsidiary Prometic...
-
Jul 9, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –July 9, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Jun 23, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 23, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A...
-
Jun 4, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced today that the U.S. Food & Drug...
-
Jun 4, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced the voting results from its Annual...
-
May 28, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
May 21, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 21, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
May 17, 2021Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M
LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 17, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
May 17, 2021Updated Business Strategy Focused on Small Molecule Therapeutics
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – May 17, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Mar 24, 2021Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – March 24, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Jan 27, 2021
Company focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics...
-
Jan 12, 2021
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – January 12, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Dec 15, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – Dec 14, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Dec 7, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – December 7, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Nov 13, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 13, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Nov 12, 2020
PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early...
-
Nov 10, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 10, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Nov 8, 2020
PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 8, 2020 – Liminal...
-
Nov 6, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 6, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Nov 5, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 5, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Oct 30, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 30, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...
-
Sep 21, 2020
FDA assigns PDUFA target action date of March 5, 2021 LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 21, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the...
-
Sep 9, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 9, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Sep 8, 2020
Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size Pending approval, potential for Ryplazim®...
-
Sep 1, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 1, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Aug 10, 2020
Acquisition of OXER1 R&D Program Joined the CoVIg-19 Plasma Alliance Voluntary Delisting from Toronto Stock Exchange Net loss from continuing operations for Q2 2020 reduced by approximately 80%...
-
Aug 6, 2020
nt at Canaccord 40th Annual Growth Conference Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference AUGUST 6, 2020 SHRINAL INAMDAR LAVAL, QC, and CAMBRIDGE, ENGLAND – August...
-
Jul 22, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 22, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jul 17, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 17, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jul 2, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 2, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jun 30, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – June 30, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jun 30, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – June 30, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jun 11, 2020
LAVAL, QC, and CAMBRIDGE, UK – June 11, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...
-
Jun 9, 2020
LAVAL, QC, and CAMBRIDGE, UK – June 9, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...
-
May 28, 2020
LAVAL, QC, and CAMBRIDGE, UK – May 28, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...
-
May 13, 2020
LAVAL, QC, and CAMBRIDGE, UK – May 13, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...
-
Mar 22, 2020
Measures taken to safeguard workforce and continuity of operations Recent FDA update on continued efforts to facilitate development of treatments LAVAL, QC and CAMBRIDGE, UK – March 22, 2020 –...
-
Mar 20, 2020
LAVAL, QC and CAMBRIDGE, UK – March 20, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company...
-
Feb 12, 2020
Fibrosis and tissue repair Obesity and non-alcoholic fatty liver disease LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 12, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL)...
-
Feb 6, 2020
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 6, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage...
-
Jan 13, 2020
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – January 13, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company” ), a clinical-stage...
-
Dec 23, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – December 23, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL) ( “Liminal BioSciences” or the “Company”), is issuing this news release in...
-
Nov 28, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 28, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL) ( “Liminal BioSciences” or the “Company” ), a clinical-stage...
-
Nov 27, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 27, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical...
-
Nov 25, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 25, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical...
-
Nov 19, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 - Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage...
-
Nov 18, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 – Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biotechnology...
-
Nov 18, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 – Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biotechnology...
-
Nov 15, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 14, 2019 – Liminal BioSciences Inc. (TSX: LMNL, NASDAQ: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...
-
Nov 15, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 15, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...
-
Nov 13, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 13, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage...
-
Nov 12, 2019
New preclinical data suggests PBI-4547 displays pleiotropic activities and has been shown to reduce non-alcoholic steatohepatitis (NASH), diabetes and fibrosis in different rodent models. LAVAL,...
-
Nov 11, 2019
Name change to Liminal BioSciences Inc. Divestment of UK bioseparations subsidiary to KKR for up to GBP 45 million in gross proceeds, of which GBP 32 million to be received upon closing Net loss...
-
Nov 11, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...
-
Nov 11, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a biopharmaceutical...
-
Nov 4, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 4, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage...
-
Oct 29, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 29, 2019 –Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage small...
-
Oct 25, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 25, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage small molecules company...
-
Oct 24, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 24, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences”), a biopharmaceutical company focused on developing novel...
-
Oct 18, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 18, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage small molecules...
-
Oct 3, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 3rd, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical company focused on...
-
Sep 9, 2019
Novel, orally active immuno-metabolic agent Potential therapy for NAFLD/NASH, metabolic syndrome and other liver diseases Fully owned and proprietary to Prometic LAVAL, CANADA, ROCKVILLE, USA and...
-
Sep 4, 2019
LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – September 4, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...
-
Sep 4, 2019
LAVAL, QUEBEC, CANADA, ROCKVILLE, MD, USA and CAMBRIDGE, UK – September 3, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical...
-
Aug 12, 2019
C$229 (US 173) million of outstanding debt converted into Common Shares C$114 (US$87) million in gross proceeds raised in concurrent financings Internal promotions within the management team for...
-
Aug 8, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 8th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), wishes to correct an error in its press release entitled...
-
Aug 7, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 7th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...
-
Aug 5, 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 5, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), a biopharmaceutical company focused on developing novel...
-
Jul 2, 2019
LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – July 2, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to announce that the...
-
Jun 20, 2019
LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – June 19, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced the voting results...
-
Jun 17, 2019
Full allocation of exercised rights Gross proceeds raised of C$38 million (or US$ 28.4 million) LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – June 17, 2019 – Prometic Life Sciences Inc. (TSX:
-
Jun 13, 2019
LAVAL, QC, CANADA, ROCKVILLE, MD, USA and CAMBRIDGE, UK – June 14, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing...
-
May 30, 2019
LAVAL, QUEBEC, CANADA; ROCKVILLE, MD, USA and CAMBRIDGE, UK – May 30, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing...
-
May 22, 2019
LAVAL, QUEBEC, CANADA and CAMBRIDGE, UK – May 22, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the...
-
May 16, 2019
LAVAL, QUEBEC, CANADA – May 15, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the terms of its previously announced equity...
-
May 9, 2019
Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering New CEO, Board appointees and management structure to strengthen Corporation’s...
-
May 8, 2019
Laval, Québec, Canada, Cambridge, UK, – May 8, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or “Corporation”) is pleased to announce today a new management...
-
Apr 23, 2019
LAVAL, QC, April 23, 2019 Stefan Clulow appointed as Chair of the Board Kenneth Galbraith appointed as Chief Executive Officer LAVAL, QC, April 23, 2019 /CNW Telbec/ - Prometic Life Sciences Inc....
-
Apr 15, 2019
LAVAL, QUEBEC, CANADA – April 15, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today its intention to enter into a series of...
-
Apr 1, 2019
Key Events for 2018:Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net...
-
Mar 26, 2019
LAVAL, QUEBEC, CANADA – March 26, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it will report its financial...
-
Mar 25, 2019
LAVAL, QUEBEC, CANADA – March 25, 2019 – Prometic Life Sciences Inc. (TSX:PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it has secured an additional USD $5...
-
Feb 25, 2019
LAVAL, QUEBEC, CANADA – February 25, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it has secured an additional USD...
-
Feb 14, 2019
LAVAL, QUEBEC, CANADA – February 14, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) today announced that it has engaged Lazard to review...